S&P 500   3,830.18 (-0.29%)
DOW   30,808.59 (-0.61%)
QQQ   326.79 (+0.42%)
AAPL   142.77 (+2.66%)
MSFT   227.09 (+0.50%)
FB   275.43 (+0.34%)
GOOGL   1,878.66 (-0.73%)
AMZN   3,294.66 (+0.07%)
TSLA   872.27 (+3.03%)
NVDA   541.06 (-1.36%)
BABA   261.50 (+1.11%)
CGC   33.22 (-1.72%)
GE   10.96 (-1.35%)
MU   80.45 (-2.22%)
AMD   93.51 (+0.78%)
NIO   60.29 (-2.68%)
T   28.87 (-0.21%)
F   11.08 (-3.82%)
ACB   10.34 (-2.91%)
BA   201.15 (-2.28%)
DIS   170.28 (-1.45%)
NFLX   558.42 (-1.19%)
GILD   66.64 (-0.45%)
S&P 500   3,830.18 (-0.29%)
DOW   30,808.59 (-0.61%)
QQQ   326.79 (+0.42%)
AAPL   142.77 (+2.66%)
MSFT   227.09 (+0.50%)
FB   275.43 (+0.34%)
GOOGL   1,878.66 (-0.73%)
AMZN   3,294.66 (+0.07%)
TSLA   872.27 (+3.03%)
NVDA   541.06 (-1.36%)
BABA   261.50 (+1.11%)
CGC   33.22 (-1.72%)
GE   10.96 (-1.35%)
MU   80.45 (-2.22%)
AMD   93.51 (+0.78%)
NIO   60.29 (-2.68%)
T   28.87 (-0.21%)
F   11.08 (-3.82%)
ACB   10.34 (-2.91%)
BA   201.15 (-2.28%)
DIS   170.28 (-1.45%)
NFLX   558.42 (-1.19%)
GILD   66.64 (-0.45%)
S&P 500   3,830.18 (-0.29%)
DOW   30,808.59 (-0.61%)
QQQ   326.79 (+0.42%)
AAPL   142.77 (+2.66%)
MSFT   227.09 (+0.50%)
FB   275.43 (+0.34%)
GOOGL   1,878.66 (-0.73%)
AMZN   3,294.66 (+0.07%)
TSLA   872.27 (+3.03%)
NVDA   541.06 (-1.36%)
BABA   261.50 (+1.11%)
CGC   33.22 (-1.72%)
GE   10.96 (-1.35%)
MU   80.45 (-2.22%)
AMD   93.51 (+0.78%)
NIO   60.29 (-2.68%)
T   28.87 (-0.21%)
F   11.08 (-3.82%)
ACB   10.34 (-2.91%)
BA   201.15 (-2.28%)
DIS   170.28 (-1.45%)
NFLX   558.42 (-1.19%)
GILD   66.64 (-0.45%)
S&P 500   3,830.18 (-0.29%)
DOW   30,808.59 (-0.61%)
QQQ   326.79 (+0.42%)
AAPL   142.77 (+2.66%)
MSFT   227.09 (+0.50%)
FB   275.43 (+0.34%)
GOOGL   1,878.66 (-0.73%)
AMZN   3,294.66 (+0.07%)
TSLA   872.27 (+3.03%)
NVDA   541.06 (-1.36%)
BABA   261.50 (+1.11%)
CGC   33.22 (-1.72%)
GE   10.96 (-1.35%)
MU   80.45 (-2.22%)
AMD   93.51 (+0.78%)
NIO   60.29 (-2.68%)
T   28.87 (-0.21%)
F   11.08 (-3.82%)
ACB   10.34 (-2.91%)
BA   201.15 (-2.28%)
DIS   170.28 (-1.45%)
NFLX   558.42 (-1.19%)
GILD   66.64 (-0.45%)
Log in
NASDAQ:RVNC

Revance Therapeutics Stock Forecast, Price & News

$28.08
-0.51 (-1.78 %)
(As of 01/25/2021 12:04 PM ET)
Add
Compare
Today's Range
$27.71
Now: $28.08▼
$28.77
50-Day Range
$23.90
MA: $27.38▼
$29.59
52-Week Range
$11.78
Now: $28.08▼
$34.62
Volume17,637 shs
Average Volume382,166 shs
Market Capitalization$1.87 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Revance Therapeutics logo

MarketRank™

Overall MarketRank™

1.47 out of 5 stars

Medical Sector

464th out of 1,923 stocks

Pharmaceutical Preparations Industry

236th out of 773 stocks

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RVNC
Previous Symbol
CUSIPN/A
CIK1479290
Webwww.revance.com
Phone510-742-3400
Employees193
Year FoundedN/A

Debt

Debt-to-Equity Ratio0.48
Current Ratio7.07
Quick Ratio7.01

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$410,000.00
Price / Sales4,557.79
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.00 per share
Price / Book5.62

Profitability

EPS (Most Recent Fiscal Year)($3.67)
Net Income$-159,430,000.00
Net Margins-5,818.87%
Return on Equity-85.72%
Return on Assets-44.85%

Miscellaneous

Outstanding Shares66,549,000
Market Cap$1.87 billion
Next Earnings Date2/22/2021 (Estimated)
OptionableOptionable
$28.08
-0.51 (-1.78 %)
(As of 01/25/2021 12:04 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

How has Revance Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Revance Therapeutics' stock was trading at $17.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RVNC stock has increased by 56.3% and is now trading at $28.08.
View which stocks have been most impacted by COVID-19.

Is Revance Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Revance Therapeutics stock.
View analyst ratings for Revance Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Revance Therapeutics?

Wall Street analysts have given Revance Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Revance Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Mark Foley's approval rating as Revance Therapeutics' CEO?

7 employees have rated Revance Therapeutics CEO Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among Revance Therapeutics' employees.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Revance Therapeutics.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its earnings results on Monday, November, 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.09) by $0.25. The biopharmaceutical company earned $3.84 million during the quarter, compared to the consensus estimate of $1.26 million. Revance Therapeutics had a negative net margin of 5,818.87% and a negative trailing twelve-month return on equity of 85.72%.
View Revance Therapeutics' earnings history.

What price target have analysts set for RVNC?

8 analysts have issued 12 month price objectives for Revance Therapeutics' stock. Their forecasts range from $15.00 to $45.00. On average, they expect Revance Therapeutics' share price to reach $33.14 in the next year. This suggests a possible upside of 18.0% from the stock's current price.
View analysts' price targets for Revance Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Revance Therapeutics' key competitors?

Some companies that are related to Revance Therapeutics include United Therapeutics (UTHR), Galapagos (GLPG), Allakos (ALLK), Schrödinger (SDGR), TG Therapeutics (TGTX), Turning Point Therapeutics (TPTX), Evotec (EVTCY), Perrigo (PRGO), Emergent BioSolutions (EBS), Blueprint Medicines (BPMC), Amicus Therapeutics (FOLD), Maravai LifeSciences (MRVI), Eidos Therapeutics (EIDX), Biohaven Pharmaceutical (BHVN) and Sage Therapeutics (SAGE).
View all of RVNC's competitors.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the following people:
  • Mr. Mark J. Foley, Pres, CEO & Director (Age 55, Pay $866.13k)
  • Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 45, Pay $621.33k)
  • Dr. Abhay Joshi, COO, Pres of R&D and Product Operations (Age 57, Pay $699.21k)
  • Mr. Dustin S. Sjuts, Chief Commercial Officer of Aesthetics & Therapeutics (Age 40, Pay $658.02k)
  • Mr. Aubrey Rankin, Pres of Innovation & Technology and Director (Age 45)
  • Mr. Dwight Moxie, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)
  • Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Taryn Conway, VP of Marketing
  • Mr. Justin Ford, Sr. VP of HR & Head of People
  • Ms. Azita Nejad, Sr. VP of Technical Operations

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Centaurus Financial Inc. (0.08%) and First Midwest Bank Trust Division (0.03%). Company insiders that own Revance Therapeutics stock include Aubrey Rankin, Cyril Allouche and L Daniel Browne.
View institutional ownership trends for Revance Therapeutics.

Which major investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division, and Centaurus Financial Inc..
View insider buying and selling activity for Revance Therapeutics or view top insider-selling stocks.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $28.08.

How big of a company is Revance Therapeutics?

Revance Therapeutics has a market capitalization of $1.87 billion and generates $410,000.00 in revenue each year. The biopharmaceutical company earns $-159,430,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Revance Therapeutics employs 193 workers across the globe.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is www.revance.com.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.